# A Study of FT-7051 in Men With MCRPC

> **NCT04575766** · PHASE1 · TERMINATED · sponsor: **Novo Nordisk A/S** · enrollment: 25 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** FT-7051

## Key facts

- **NCT ID:** NCT04575766
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-30
- **Primary completion:** 2022-11-08
- **Final completion:** 2022-11-15
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2023-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04575766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04575766, "A Study of FT-7051 in Men With MCRPC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04575766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*